ANI Pharmaceuticals Q3: Record Revenue, Growth in Rare Disease & Generics
Update: 2025-11-14
Description
ANI Pharmaceuticals delivered robust third-quarter results, with significant growth in Rare Disease and Generics segments. Cortrophin Gel net revenue nearly doubled, boosted by a major generic launch, record new patient starts, and increased prescriber adoption in pulmonology and ophthalmology. The company reported revenue of $227.8 million, beating estimates by $13 million, and adjusted earnings per share of $2.04, surpassing expectations by $0.27. Adjusted EBITDA also exceeded predictions, reaching $59.6 million. ANI raised full-year revenue guidance to $863.5 million and adjusted earnings per share guidance to $7.51. Key growth drivers include pulmonology, sales force expansion, and prefilled syringe adoption. Future focus areas are Cortrophin Gel adoption in new specialties, ILUVIEN sales stabilization, and generic launch and competitive dynamics.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
